×
Customize
?
Start
Cancer Types
Quick Links
Award Programs
Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873
Copyright © 2018
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873
Copyright © 2018
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.
Non-Hodgkin Lymphoma
Kristie L. Kahl
A national survey demonstrated shared feelings across all blood cancer types about treatment options and their side effects, as well as other social, financial and emotional aspects.
Peter Borchmann, M.D.
CAR-T cell therapy is generating excitement for the treatment of diffuse large B-cell lymphoma, according to an update from the JULIET trial.
Shira Zwebner
How do you stay positive when surrounded by death and dying?
Jason M. Broderick
The FDA has granted a priority review to a supplemental new drug application (sNDA) Imbruvica (ibrutinib) for use in combination with Rituxan (rituximab) as a treatment option across all lines of therapy for patients with Waldenström macroglobulinemia.
Katie Kosko
Treatment with chimeric antigen receptor (CAR)-T cell therapy showed encouraging rates of durable responses among adult patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL), according to updated data from the pivotal JULIET trial.
Shira Zwebner
Why the proverb, "you should never judge a man until you've walked a mile in his shoes" is true for both cancer patients and survivors.
Brielle Urciuoli
Dewayne Johnson is the first of hundreds of patients to take Monsanto to trial, claiming that Roundup caused them to get cancer. His case will be seen even sooner than others because in California dying plaintiffs can be given expedited trials.
The FDA has granted an accelerated approval to Keytruda (pembrolizumab) for the treatment of adult and pediatric patients with refractory primary mediastinal large B-cell lymphoma (PMBCL), or those who have relapsed after 2 or more prior lines of therapy.
Kristie L. Kahl
In this week’s episode of CURE Talks Cancer, we spoke with Matt Lashey, creator and CEO of the chemoWave app, which is designed to manage cancer symptoms and conditions by keeping track of a patient’s overall well-being to understand how their experiences may be related to feeling better or worse during treatment.